

Overview of Continuous Subcutaneous Apomorphine Infusion (Onapgo™) Peer-Reviewed Publications

Phase 3	
TOLEDO Study Primary Publication ¹	The safety and efficacy of CSAI were demonstrated in a 12-week, double-blind, placebo-controlled trial in PD patients with persistent motor fluctuations, allowing substantial reductions in oral PD medications.
Phase 3 Open label	
TOLEDO Study Primary Publication ²	The long-term safety and efficacy of CSAI were demonstrated in a 52-week, open-label study in PD patients with persistent motor fluctuations, with similar reductions in oral PD medications
InfusON Study Primary Publication ³	The long-term safety and efficacy of CSAI were demonstrated in a 52-week, open-label study in PD patients with persistent motor fluctuations.
Britannia-sponsored study	
Nighttime CSAI ⁴	The safety and efficacy of night-time CSAI on sleep disturbances in PD patients with moderate to severe insomnia
Post-Hoc Analyses	
TOLEDO + RWE ⁵	Post-hoc analysis of TOLEDO study and analysis of real-world experience with CSAI
OPTIPump ⁶	Prospective, open-label, observational cohort study evaluating the impact of CSAI on health-related quality of life measures
Retrospective analysis ⁷	Use of CSAI in patients with previous impulsive-compulsive behaviors ICBs
Observational study ⁸	A single-center, long-term observational study evaluating the reasons for CSAI discontinuation
Retrospective analysis ⁹	A retrospective analysis of long-term CSAI efficacy and reasons for discontinuation
Retrospective evaluation ¹⁰	Retrospective analysis of the frequency of ICBs in patients treated with continuous waking day CSAI

Abbreviations: CSAI: Continuous subcutaneous apomorphine infusion; ICD: impulsive compulsive behaviors; PD: Parkinson's Disease; RWE: Real World Evidence

References:

1. Katzenschlager R. *Lancet Neurol.* 2018;17(9):749-759. 2. Katzenschlager R. *Parkinsonism Relat Disord.* 2021;83:79-85. 3. Isaacson S. *J Park Dis.* 2025;X:xxx. 4. De Cock, VC. *Lancet Neurol.* 2022;21(5):428-437. 5. Henriksen, T. *J Neural Transm (Vienna).* 2023;130(11):1475-1484. 6. Drapier, S. *J Neurol.* 2016;263(6):1111-9. 7. Barbosa, P. *Arq Neuropsiquiatr.* 2022;80(1):56-61. 8. Henriksen, T. *J Pers Med.* 2021;11(6):525. 9. Bhidayasiri, R. *Clin Neuropharmacol.* 2019;42(5):172-178. 10. Barbosa, P. *Mov Disord Clin Pract.* 2016;4(3):323-328.